Adjuvant chemotherapy for locally advanced bladder cancer

John D. Cant, Maurizio Brausi, Mark S. Soloway

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although controversy over the relative efficacy of full-dose pelvic radiation and radical cystectomy, with or without pre-operative radiation, continues, none of these treatments directed only at the disease in the pelvis cures more than 50 percent of patients with locally advanced disease. An effective systemic therapy is needed. The most effective single agent in metastatic bladder cancer, Cis-platin, has not altered the cure rate when used as an adjuvant. Limited trials using Cis-platin based three and four drug combination chemotherapy regimens have yielded 50-70 percent overall response rates with 30 percent complete responses in metastatic disease. It seems appropriate to perform pilot studies using these more intensive programs as adjuvant chemotherapy for good performance status patients at high risk of progression, e.g. positive lymph nodes.

Original languageEnglish
Pages (from-to)115-120
Number of pages6
JournalWorld Journal of Urology
Volume3
Issue number2
DOIs
StatePublished - Sep 1 1985
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Urinary Bladder Neoplasms
Radiation
Cystectomy
Drug Combinations
Combination Drug Therapy
Pelvis
Lymph Nodes
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Adjuvant chemotherapy for locally advanced bladder cancer. / Cant, John D.; Brausi, Maurizio; Soloway, Mark S.

In: World Journal of Urology, Vol. 3, No. 2, 01.09.1985, p. 115-120.

Research output: Contribution to journalArticle

Cant, John D. ; Brausi, Maurizio ; Soloway, Mark S. / Adjuvant chemotherapy for locally advanced bladder cancer. In: World Journal of Urology. 1985 ; Vol. 3, No. 2. pp. 115-120.
@article{38ead939f71f4e979ad75b6ee49aad04,
title = "Adjuvant chemotherapy for locally advanced bladder cancer",
abstract = "Although controversy over the relative efficacy of full-dose pelvic radiation and radical cystectomy, with or without pre-operative radiation, continues, none of these treatments directed only at the disease in the pelvis cures more than 50 percent of patients with locally advanced disease. An effective systemic therapy is needed. The most effective single agent in metastatic bladder cancer, Cis-platin, has not altered the cure rate when used as an adjuvant. Limited trials using Cis-platin based three and four drug combination chemotherapy regimens have yielded 50-70 percent overall response rates with 30 percent complete responses in metastatic disease. It seems appropriate to perform pilot studies using these more intensive programs as adjuvant chemotherapy for good performance status patients at high risk of progression, e.g. positive lymph nodes.",
author = "Cant, {John D.} and Maurizio Brausi and Soloway, {Mark S.}",
year = "1985",
month = "9",
day = "1",
doi = "10.1007/BF00326719",
language = "English",
volume = "3",
pages = "115--120",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Adjuvant chemotherapy for locally advanced bladder cancer

AU - Cant, John D.

AU - Brausi, Maurizio

AU - Soloway, Mark S.

PY - 1985/9/1

Y1 - 1985/9/1

N2 - Although controversy over the relative efficacy of full-dose pelvic radiation and radical cystectomy, with or without pre-operative radiation, continues, none of these treatments directed only at the disease in the pelvis cures more than 50 percent of patients with locally advanced disease. An effective systemic therapy is needed. The most effective single agent in metastatic bladder cancer, Cis-platin, has not altered the cure rate when used as an adjuvant. Limited trials using Cis-platin based three and four drug combination chemotherapy regimens have yielded 50-70 percent overall response rates with 30 percent complete responses in metastatic disease. It seems appropriate to perform pilot studies using these more intensive programs as adjuvant chemotherapy for good performance status patients at high risk of progression, e.g. positive lymph nodes.

AB - Although controversy over the relative efficacy of full-dose pelvic radiation and radical cystectomy, with or without pre-operative radiation, continues, none of these treatments directed only at the disease in the pelvis cures more than 50 percent of patients with locally advanced disease. An effective systemic therapy is needed. The most effective single agent in metastatic bladder cancer, Cis-platin, has not altered the cure rate when used as an adjuvant. Limited trials using Cis-platin based three and four drug combination chemotherapy regimens have yielded 50-70 percent overall response rates with 30 percent complete responses in metastatic disease. It seems appropriate to perform pilot studies using these more intensive programs as adjuvant chemotherapy for good performance status patients at high risk of progression, e.g. positive lymph nodes.

UR - http://www.scopus.com/inward/record.url?scp=0022261990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022261990&partnerID=8YFLogxK

U2 - 10.1007/BF00326719

DO - 10.1007/BF00326719

M3 - Article

VL - 3

SP - 115

EP - 120

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 2

ER -